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Information on the long-term health of living liver donors is incomplete. Because changes in standard laboratory tests may
reflect the underlying health of donors, results before and after donation were examined in the Adult-to-Adult Living Donor
Liver Transplantation Cohort Study (A2ALL). A2ALL followed 487 living liver donors who donated at 9 US transplant centers
between 1998 and 2009. The aminotransferase [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)]
and alkaline phosphatase (AP) activities, bilirubin, international normalized ratio (INR), albumin, white blood cell count
(WBC), hemoglobin (HGB), platelet count, ferritin, serum creatinine (SCR), and blood urea nitrogen (BUN) were measured
at the evaluation and after donation (1 week, 1 month, 3 months, 1 year, and yearly thereafter). Repeated measures models
were used to estimate median laboratory values at each time point and to test for differences between values at the evalua-
tion (baseline) and postdonation time points. Platelet counts were significantly decreased at every time point in comparison
with the baseline, and at 3 years, they were 19% lower. Approximately 10% of donors had a platelet count < 150  1000/
mm3 2 to 3 years post-donation. Donors with a platelet count  150  1000/mm3 at 1 year had significantly lower mean
platelet counts (189 6 32  1000/mm3) versus the remainder of the cohort (267 6 56  1000/mm3, P < 0.0001) at the
evaluation. Statistically significant differences compared to the evaluation values were noted for AST, AP, INR, and albumin
through the first year, although most measurements were in the normal range. The median values for WBC, HGB, ferritin,
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver Transplantation Cohort Study; ALT, alanine aminotransferase; AP, alka-
line phosphatase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; GW/TLV, graft weight to total liver volume ratio;
HGB, hemoglobin; INR, international normalized ratio; LLN, lower limit of normal; SCR, serum creatinine; ULN, upper limit of nor-
mal; WBC, white blood cell count.
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albumin, SCR, BUN, and INR were not substantially outside the normal range at any time point. In conclusion, after 3
months, most laboratory values return to normal among right hepatic lobe liver donors, with a slower return to baseline lev-
els for AST, AP, INR, and albumin. Persistently decreased platelet counts warrant further investigation. Liver Transpl
17:409-417, 2011. VC 2011 AASLD.
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Donor safety is paramount to the success of living donor
liver transplantation. Thus, it is imperative that trans-
plant physicians have a complete understanding of
potential complications in living donors so that the risk of
the procedure can be accurately described to donor can-
didates and steps can be taken tomitigate that risk. Early
in the experience of the procedure, reported complication
rates1,2 were relatively low (estimated to be 10%-20%),
but reports may have underestimated complications as a
result of incomplete data collection and underreporting.
In addition, the full spectrum and prevalence of compli-
cations may have been underappreciated because of the
relatively small numbers of patients studied and their
short follow-up intervals. A subsequent and more com-
prehensive study reported a substantially higher overall
complication rate of 38%; 2% and 0.8% of these compli-
cations were grades 3 and 4 (serious), respectively.3
Routine clinical laboratory tests are performed reg-
ularly after living donor hepatectomy to determine a
patient’s return to health and to detect postdonation
complications. However, there is little information on
either the patterns of laboratory test results or their
abnormalities. One single-center study of a subset of
the donors reported herein reported results of laboratory
tests for up to 1 year after surgery.4 Among 70 living liver
donors in that study, 22 were evaluated 1 year post-dona-
tion. Only 1 donor had abnormal liver test results, but 5
(23%) had thrombocytopenia (platelet count < 150 
1000/mm3). Because of this relative paucity of informa-
tion, we undertook this study to describe the long-term
changes in common laboratory tests for living liver donors
enrolled in the Adult-to-Adult Living Donor Liver Trans-
plantation Cohort Study (A2ALL). Because A2ALL enrolled
donors before liver donation and attempted regular follow-
up afterward, it has the ability to identify changes in labo-
ratory results and their abnormalities. The major aims of
this study were (1) to improve our understanding of
potential long-term donor complications and (2) to provide
donors with more information on laboratory abnormalities
after liver transplantation.
PATIENTS AND METHODS
Protocol and Data Collection
This study included information on the 487 living donors
enrolled in A2ALL for the 12-year period from 1998
through 2009 at 9 US transplant centers. Data were
recorded by each of the participating transplant centers
according to a common protocol. Through October 2004,
all donor laboratory results were collected retrospectively
from medical records. Laboratory results collected after
October 2004 were a mixture of retrospective (in the case
of patient consent after the initial donor evaluation) and
prospective data collection. The prospective protocol
specified the blood tests to be performed at the initial
evaluation and at 1 week, 1 month, 3 months, 12
months, and yearly post-donation. Collected laboratory
values included the following: alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phatase (AP), total bilirubin, international normalized ra-
tio (INR), albumin, platelet count, white blood cell count
(WBC), ferritin, hemoglobin (HGB), serum creatinine
(SCR), and blood urea nitrogen (BUN).
The upper (ULN) and lower (LLN) limits of normal dif-
fered at the 9 A2ALL centers. The ranges and the values
chosen for presenting the percents above or below nor-
mal were as follows: 41 to 75 (ULN) and 47 IU/L for ALT,
35 to 59 (ULN) and 47 IU/L for AST, 1.1 to 1.3 (ULN) and
1.3 mg/dL for total bilirubin, 96 to 150 (ULN) and 117
IU/L for AP, 140 to 172 (LLN) and 150  1000/mm3 for
the platelet count, 3.4 to 4.0 (LLN) and 3.4 g/dL for albu-
min, and 1.1 to 1.2 (ULN) and 1.1 for INR.
Protection of Human Subjects
This study was approved by the institutional review
boards and privacy boards of each of the 9 participating
TABLE 1. Characteristics of 487 Liver Transplant















African American 14 3%
Asian 9 2%
Other 33 7%
Height (cm)* 479 171.7 (10) 134.6-195.6
Weight (kg)* 478 77.1 (14.5) 43.1-135
Body mass index
(kg/m2)*
475 26.3 (3.9) 13.8-42.5
*Data were missing for less than 2.5%.
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transplant centers and the University of Michigan Data
Coordinating Center. Researchers began to obtain the
consent of past donors (for retrospective data) and donor
candidates (for prospective data) in September 2004.
Statistical Analysis
The distributions of laboratory values over time are
shown as box plots with whiskers extending to the
5th and 95th percentiles. Scatter plots of week 1,
month 1, and year 1 values versus the baseline values
are shown for selected laboratory tests. Pearson corre-
lation coefficients were used to estimate the strength
of the linear relationship between WBCs and platelet
counts at several time points. Differences between the
number of abnormal values at the baseline and at the
first follow-up at least 1 year later among patients
without missing values at both time points were
examined with McNemar’s test for paired data. Exact
conditional logistic regression was used to estimate
the odds ratios and 95% confidence intervals for
abnormal laboratory results at follow-up versus the
baseline. A repeated measures model using the SAS
mixed procedure (SAS Institute, Inc., Cary, NC) was
used to estimate median laboratory values over time
and to test for significant changes in postdonation
values from the baseline. This model used a Toeplitz
covariance structure for repeated measurements of
the same subject over time and remained valid in the
presence of randomly missing laboratory values. For
statistical testing, all laboratory values were log-trans-
formed to remove skewness. All analyses were per-
formed with SAS version 9.2 (SAS Institute).
RESULTS
Among the 487 living donors, the mean donor age was
37.6 years (range ¼ 18-62 years), 88% were white
(Table 1), and 62% were biologically related. Of the 487
donors, 486 had baseline, predonation laboratory
results, and 466 (94%) had laboratory results from at
least 1 postdonation time point (235 from 4 or more
time points, 123 from 3, 76 from 2, and 32 from 1).
Figures 1A-D and 2A-C depict the distributions of
laboratory values over time from donation through year
4. The greatest changes occurred in the immediate
Figure 1. Laboratory tests at the evaluation and 7 time points post-donation: (A) ALT, (B) AST, (C) AP, and (D) total bilirubin.
Asterisks just above the x axis indicate time points at which the median was significantly different from the evaluation value (P <
0.05). Boxes include the 25th to 75th percentiles, with indentations indicating medians and plus signs indicating mean values
(connected by gray lines). Whiskers extend to the 5th and 95th percentiles.
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postoperative period, as shown in the week 1 levels,
and most values approached baseline levels by 3
months. However, statistically significant differences in
median values versus baseline values were noted for
up to 1 year for AST, AP, total bilirubin, INR, and albu-
min. Platelet counts were significantly lower than those
before liver transplantation at each of the follow-up
intervals (Fig. 2C). The average reduction in the platelet
count from the baseline to year 4 was 16%.
Figures 3A-D and 4A-C show scatter plots of the
laboratory values at year 1 plotted against baseline
values for each patient. Points below the equivalence
line indicate patients whose 1-year values were lower
than the baseline, and points above the line indicate
1-year values that were higher than the baseline. For
ALT and INR, the distribution is equally displaced
around the equivalence line, and this suggests that
there was no overall shift in values between the base-
line and 1 year. Figure 5A,B shows the week 1 and
month 1 INR values plotted against baseline values;
INR increased substantially by week 1 but was nearly
back to normal by month 1. The variances of the dis-
tributions of AST (P < 0.0001), AP (P < 0.0001), and
bilirubin (P ¼ 0.09) were larger at 1 year versus the
baseline, mostly because of more outliers at 1 year.
Albumin showed a modest shift downward but no dif-
ference in the variance between the baseline and 1-
year values (P ¼ 0.39). Figure 5C,D show the week 1
and month 1 albumin values plotted against the base-
line values; albumin decreased substantially by week
1 and recovered only partially by month 1. The most
striking changes occurred in the platelet count: there
was an obvious downward shift in the platelet distri-
bution post-donation and a significant decrease in
variance (P ¼ 0.004) at 1 year versus the baseline
(Fig. 4C). In comparison with the baseline, 89.4% of
the patients had lower platelet counts at 1 year.
Donors with a platelet count < 150  1000/mm3 at 1
year had a significantly lower mean platelet count at
the evaluation (189 6 32  1000/mm3) in comparison
with the remainder of the cohort (267 6 56  1000/
mm3, P < 0.0001).
To further investigate the relationships shown in
Figs. 3 and 4, we compared abnormal laboratory val-
ues at the baseline and at the first follow-up visit that
occurred 1 year or more post-donation (Table 2), and
we tested the likelihood of previously normal values
becoming abnormal versus the likelihood of previ-
ously abnormal values becoming normal. Significantly
more abnormal values were found at 1 year or later
for the platelet count, AST, and albumin, and nearly
significant results were found for AP and total biliru-
bin (P ¼ 0.07 and 0.08, respectively)
For all 7 laboratory measures, the covariates that
were tested for their ability to predict the difference
between the 1-year and baseline values included age,
sex, weight at the baseline, weight changes between
the baseline and 1 year, baseline values, and interac-
tions between these variables and baseline values.
Donors tended to gain weight after donation
(mean ¼ 1.0 kg, standard deviation ¼ 5.7 kg, P ¼
0.02). A 10-year older age was associated with higher
values at 1 year for ALT (b ¼ 1.9 IU/L, P ¼ 0.011),
AST (b ¼ 1.7 IU/L, P ¼ 0.001), and AP (b ¼ 4.5 IU/L,
P ¼ 0.0003) and with lower values for albumin (b ¼
0.06 g/dL, P ¼ 0.006). Women had lower values at 1
year for bilirubin and albumin by averages of 0.13
mg/dL (P ¼ 0.0008) and 0.11 g/dL (P ¼ 0.030),
Figure 2. Laboratory tests at the evaluation and 7 time points
post-donation: (A) INR, (B) albumin, and (C) platelet count.
Asterisks just above the x axis indicate time points at which the
median was significantly different from the evaluation value (P <
0.05). Boxes include the 25th to 75th percentiles, with
indentations indicating medians and plus signs indicating mean
values (connected by gray lines). Whiskers extend to the 5th and
95th percentiles.
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respectively. Baseline values were highly predictive of
values at 1 year for all laboratory measures; this is
obvious in Figs. 3 and 4 (P < 0.05 for all and P <
0.0001 for most). The weight change from the baseline
was significantly predictive of AP (b ¼ 0.64/kg, P ¼
0.013) and was close to significant for ALT (b ¼ 0.30/
kg, P ¼ 0.082) and bilirubin (b ¼ 0.006/kg, P ¼
0.086). No other factors were predictive of changes in
platelets from the baseline to 1 year.
We further tested the correlation between platelet
counts and WBCs, which would be expected if the
drop in platelet counts were related to portal hyper-
tension. We found significant correlations (P < 0.0001
for all) at all time points tested (through year 3), and
most were substantially larger than the correlation
seen at the baseline (r ¼ 0.23): r ¼ 0.32 at 1 week, r ¼
0.40 at 1 month, r ¼ 0.22 at 3 months, r ¼ 0.35 at 1
year, r ¼ 0.45 at 2 years, and r ¼ 0.43 at 3 years.
Because a higher graft weight to total liver volume
ratio (GW/TLV) had been associated with both a
larger spleen volume and lower platelet counts after
donation,5 we tested the correlation between GW/TLV
and the platelet count at each postdonation time point
divided by the baseline count. The early postdonation
correlations were significant, but the correlations at 1
year and beyond were not (week 1, r ¼ 0.16, P ¼
0.011; month 1, r ¼ 0.19, P ¼ 0.004; month 3, r ¼
0.21, P ¼ 0.003; year 1, r ¼ 0.09; P ¼ 0.29; year 2,
r ¼ 0.03, P ¼ 0.83; and year 3, r ¼ 0.08, P ¼ 0.60).
We also tested GW/TLV in the previously reported
year 1 platelet regression model, but it was not signifi-
cant (P ¼ 0.853). However, in similar models for
months 1 and 3, GW/TLV was a significant predictor
of a reduction in platelets. With an increase of 0.10 in
GW/TLV, the platelet counts were lower on average by
12.6  1000/mm3 at 1 month (P ¼ 0.013) and by 7.0
1000/mm3 at 3 months (P ¼ 0.013). Left lobe
donors (n ¼ 24) had lower GW/TLV values (P <
0.0001) and higher platelet counts at 1 week (P ¼
0.029) than right lobe donors. Platelet counts were
not significantly different at subsequent time points
between left and right lobe donors.
Additional laboratory tests were analyzed (WBC, fer-
ritin, HGB, SCR, and BUN), but they are not reported
in detail because the findings are less likely to be clin-
ically relevant. The median values of these tests
Figure 3. Laboratory values at year 1 versus the baseline: (A) ALT (ULN ¼ 47 IU/L, n ¼ 198), (B) AST (ULN ¼ 47 IU/L, n ¼ 200), (C)
AP (ULN ¼ 117 IU/L, n ¼ 199), and (D) total bilirubin (ULN ¼ 1.3 mg/dL, n ¼ 200). The diagonal lines are lines of equality: points
below the lines indicate larger values at the baseline, and points above the lines indicate larger values at year 1.
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followed trends similar to those of the laboratory
medians already discussed. Median SCR, BUN, and
HGB values all dropped significantly from the baseline
to week 1 and recovered gradually to baseline values
by year 1 (SCR and BUN) or year 2 (HGB). WBC
peaked significantly at week 1 and then returned to
baseline values by month 1. Ferritin did not stabilize
until year 2: it peaked at week 1, then descended
below the baseline value through month 3, and slowly
increased to approach the baseline value by year 2.
DISCUSSION
There are 2 important observations from our analy-
ses. First, except for the platelet count, laboratory val-
ues approached baseline levels within 90 days after
donation. Although statistically significant differences
in median values versus evaluation values were noted
for up to 1 year for AST, AP, total bilirubin, INR, and
albumin, these differences at 1 year were very small
numerically and were likely clinically irrelevant. This
information should be reassuring to donors and donor
candidates as well as their physicians. Second, we
found a significant reduction in the platelet count.
The etiology of the low platelet count is unclear,
although there are several possibilities. First, some
donors could have elevated portal pressure. This
could be caused by inadequate regeneration of the he-
patic remnant and a small remnant size, relative por-
tal or hepatic venous insufficiency, or sinusoidal
hyperperfusion, which could lead to increased portal
pressure, splenomegaly, and a reduced platelet count.
Second, thrombopoietin, the growth factor responsible
for platelet production, is produced in the liver. A
small study of 10 right hepatic lobe living donors
found that thrombopoietin levels, peaking 7 days after
surgery, doubled from 12 to 24 fm/mL.6 The increase
in thrombopoietin corresponded to a doubling of the
platelet count. If postoperative hepatic regeneration is
incomplete, a reduction in the hepatic mass could
lead to reduced thrombopoietin levels and a reduction
in the platelet count. Finally, portal vein thrombosis
has been reported in less than 1% of living liver
donors. Complete thrombosis or partial stenosis of
the portal vein could result in splenomegaly and sub-
sequent thrombocytopenia.2,4,7,8
Numerous studies have reported changes in labora-
tory tests immediately after hepatic lobe donation. As
noted previously, all but one study4 measured values
in the immediate postoperative period (<30 days).
Peak values of AST and ALT were noted on the day of
surgery or on the day after surgery9-15 and then
returned to normal values (or approached normal val-
ues) between 5 days and 1 month. In comparison
with AST and ALT, maximum postoperative bilirubin
values generally occurred somewhat later: bilirubin
peaked between 1 and 7 days and then returned to
normal or nearly normal values between 7 and 30
days.9-11,13,14,16,17 The INR or prothrombin time was
evaluated in fewer studies; it reached a peak 1 to 2
days after surgery and returned to or approached
baseline levels 7 to 14 days after surgery.9-11,13-15,17
The platelet count dropped in up to one-half of
patients and reached a nadir at approximately 3
days.5,6,11,15 Its values returned to or approached
normal levels by 30 days, but this was evaluated in
Figure 4. Laboratory values at year 1 versus the baseline: (A)
INR (ULN ¼ 1.1, n ¼ 178), (B) albumin (LLN ¼ 3.4 g/dL, n ¼
192), and (C) platelet count (LLN ¼ 150  1000/mm3, n ¼ 192).
The diagonal lines are lines of equality: points below the lines
indicate larger values at the baseline, and points above the lines
indicate larger values at year 1.
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Figure 5. Laboratory values in (A,C) week 1 and (B,D) month 1 versus the baseline: (A) INR (ULN ¼ 1.1, n ¼ 305), (B) INR (ULN ¼ 1.1,
n ¼ 277), (C) albumin (LLN ¼ 3.4 g/dL, n ¼ 310), and (D) albumin (LLN ¼ 3.4 g/dL, n ¼ 317). The diagonal lines are lines of equality:
points below the lines indicate larger values at the baseline, and points above the lines indicate larger values at year 1.
TABLE 2. Abnormal Laboratory Values Among Donors With Values Both at the Baseline (Before Donation) and at the


























ALT 333 18 (5%) 28 (8%) 12 (4%) 22 (7%) 0.09 1.8 (0.87, 4.06)
AST 332 0 (0%) 14 (4%) 0 (0%) 14 (4%) 0.0001 19.7 (3.32, 1)‡
AP 332 11 (3%) 19 (6%) 6 (2%) 14 (4%) 0.07 2.3 (0.84, 7.41)
Total bilirubin 331 12 (4%) 18 (5%) 3 (1%) 9 (3%) 0.08 3.0 (0.75, 17.2)
INR 310 15 (5%) 18 (6%) 13 (4%) 16 (5%) 0.58 1.2 (0.56, 2.78)
Albumin 324 1 (<1%) 8 (2%) 1 (<1%) 8 (2%) 0.02 8.0 (1.07, 355)
Platelet count 327 5 (2%) 24 (7%) 2 (1%) 21 (6%) <0.0001 10.5 (2.57, 92.4)
*A significant result indicated significantly more abnormal values at 1 year or later versus the baseline (the paired values
for each person were considered).
†Odds ratios (comparing the odds of an abnormal value at the first follow-up 1 year after donation or later versus the
baseline) and 95% confidence intervals were generated with exact conditional logistic regression models.
‡Because there were no abnormal AST values at the baseline, the upper limit of the confidence interval was infinite. The P
value was calculated with exact conditional logistic regression instead of McNemar’s test.
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only 1 study. Spleen size was evaluated in a few stud-
ies and increased 34% to 52% from the baseline size
by 7 days to 6 months.6,18,19 Spleen measurements
were not available for our analyses but are being
undertaken.
Our analysis differed in several important respects
from previously published reports. The number of
donors evaluated in the aforementioned studies was
relatively small; the mean and median numbers were
88 and 52, respectively. In addition, these studies
evaluated changes in laboratory tests only in the im-
mediate postoperative period and rarely after more
than 14 days. None made statistical comparisons
between baseline and follow-up values. As a result,
the changes in laboratory tests over time were largely
descriptive and not quantitative. However, these stud-
ies reported more values during the immediate post-
operative period (usually on a daily basis) than our
study. Therefore, our study likely did not capture the
greatest changes, which typically occurred within 7
days of the operation. In this respect, the most strik-
ing difference between our study and other published
reports concerns platelet counts. In earlier studies,
the platelet count increased from the baseline in the
first 1 to 3 postoperative days and decreased there-
after. Because our analysis did not report values
before day 7, we may have missed an immediate but
transient postoperative increase in the platelet count.
Our study has follow-up data for a much longer pe-
riod of time for a large number of donors at specified
intervals long after 30 days post-donation.
Our analysis has several shortcomings. We do not
have data for the immediate postoperative period (<7
days) when the greatest changes are noted in labora-
tory tests. In addition, not every donor had data for
each of the follow-up intervals. This could lead to
underreporting of abnormal tests of donors with com-
plications or could lead to overestimates of abnormal-
ities if those with normal values were less likely to be
tested. Also, follow-up laboratory tests were performed
at multiple clinical laboratories. The baseline and 1-
week values were measured at the transplant center
performing the donation. Thereafter, some tests were
done outside the transplant center, and this added
some variability because the normal value ranges for
each test differed among the clinical laboratories. We
also noted that a small percentage of donors underwent
living liver donation with mild abnormalities in their
baseline laboratory tests at the time of their operation
(most commonly ALT, bilirubin, and INR). However, the
number of patients with these abnormalities was insuf-
ficient to make any meaningful observations about
outcomes.
In conclusion, we found that most blood tests (aside
from the platelet count) returned to the normal range
and approached baseline levels within 1 year of opera-
tion in living liver donors, although the probability of
abnormal values remained elevated for AST, AP, INR,
and albumin. The cause of low platelet counts in liv-
ing liver donors warrants further evaluation. This in-
formation may be used by donors, donor candidates,
and their physicians for the further understanding of
outcomes following live liver donation.
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